Detalhe da pesquisa
1.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
N Engl J Med
; 384(6): 512-520, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33567191
2.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med
; 384(12): 1101-1112, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761207
3.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
J Am Acad Dermatol
; 90(5): 986-993, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38253129
4.
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
J Am Acad Dermatol
; 88(5): 1008-1016, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574595
5.
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
Br J Dermatol
; 186(6): 1047-1049, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041213
6.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet
; 396(10246): 255-266, 2020 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711801
7.
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.
Exp Dermatol
; 30(11): 1650-1661, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003519
8.
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
J Am Acad Dermatol
; 85(4): 847-853, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090959
9.
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
J Am Acad Dermatol
; 85(4): 863-872, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957195
10.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
J Am Acad Dermatol
; 85(1): 62-70, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600915
11.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
J Am Acad Dermatol
; 82(2): 377-388, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374300
12.
Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
J Drugs Dermatol
; 19(11): 1093-1100, 2020 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33196758
13.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
N Engl J Med
; 375(5): 422-34, 2016 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27518661
14.
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
J Am Acad Dermatol
; 80(4): 913-921.e9, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29410014
15.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
NEJM Evid
; 3(3): EVIDoa2300155, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38335032
16.
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.
JAMA Dermatol
; 160(2): 156-163, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38117526
17.
ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.
JID Innov
; 4(2): 100251, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299059
18.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
JAMA Dermatol
; 159(6): 613-620, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133856
19.
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
Dermatol Ther (Heidelb)
; 12(9): 2077-2085, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35933552
20.
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Immunotherapy
; 14(1): 5-14, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775830